Dr. Katz Sand joined the CGD Center as a
fellow in 2011. She received her
undergraduate degree from the Wharton
School of the University of Pennsylvania, where she was elected to the Beta
Gamma Sigma Honor Society. She obtained
her MD degree from Columbia University College of Physicians and Surgeons where
she was elected to the AOA Honor Society and the Arnold P. Gold Humanism in
Medicine Honor Society in 2007. She received the Helen Sciarra Prize in
Neurology and the Glasgow-Rubin Achievement Award for Women Graduating in the
Top 10% of Class. She completed
her neurology residency at Columbia University Medical Center, where she was elected chief resident in her final
year and was recognized by the Arnold P. Gold Humanism Foundation Circle of
Excellence in Teaching. She then
pursued a two-year fellowship in Multiple Sclerosis at the CGD Center, funded
by a Sylvia Lawry Fellowship Training Grant from the National Multiple
Sclerosis Society. She joined the
faculty at Mount Sinai following completion of her fellowship in 2013.
Dr. Katz Sand has a clinical practice at the CGD Center where she cares for patients with multiple sclerosis (MS), neuromyelitis optica (NMO), and other autoimmune diseases that affect the central nervous system. She is heavily involved in research, and is currently the Principal Investigator on several studies at the Center where she collaborates with other clinicians as well as with Drs. Patrizia Casaccia and Matilde Inglese, with a focus on translational research. Current research projects include studies on the mechanisms of neuronal degeneration in progressive MS, an investigation of the role of the gut microbiome in MS, as well as a clinical trial for NMO. Her work has been published in medical journals and she has presented at conferences including ECTRIMS and the AAN’s annual meeting. In addition to her own projects, Dr. Katz Sand participates in MS clinical trials. She is also involved in education, teaching residents and medical students at Mount Sinai, and lectures on MS and NMO to other physicians and patients.
Neurology, American Board of Psychiatry and Neurology
Autoimmunity, B Cells, Cellular Immunity, Demyelination, Genetics, Imaging, Multiple Sclerosis, T Cells
MD, Columbia University College of Physicians & Surgeons
Internship, Internal Medicine
New York Presbyterian Hospital
New York Presbyterian Hospital
Fellowship, Multiple Sclerosis
Mount Sinai Hospital
An open label, add-on trial of cetirizine for patients with neuromyelitis optica
Cetirizine is already known to be safe and well-tolerated in the general population. In this study, we plan to add cetirizine on to patients' current neuromyelitis optica (NMO) treatment. We aim to show that it is safe, well-tolerated, and that with cetirizine, NMO pa...
A Multicenter Global Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)
This study is being done to gain a better understanding of the benefits and risks of long-term treatment with Tecfidera™ in patients with multiple sclerosis (MS). The main purpose of this observational study is to collect information on any serious side effects that may occur in ...
Katz Sand I. Neuromyelitis Optica Spectrum Disorders. Continuum (Minneapolis, Minn.) 2016 Jun; 22(3).
Katz Sand I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Current opinion in neurology 2015 Jun; 28(3).
Farber RS, Katz Sand I. Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. Therapeutic advances in neurological disorders 2015 Sep; 8(5).
Weisfeld-Adams JD, Katz Sand IB, Honce JM, Lublin FD. Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain : a journal of neurology 2015 Mar; 138(Pt 3).
Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain : a journal of neurology 2014 Aug; 137(Pt 8).
Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 Oct; 20(12).
Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua le, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, de Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PloS one 2014; 9(3).
Katz Sand IB, Lublin FD. Diagnosis and differential diagnosis of multiple sclerosis. Continuum (Minneapolis, Minn.) 2013 Aug; 19(4 Multiple Sclerosis).
Katz Sand I, Krieger S. Emerging strategies for the treatment of multiple sclerosis. Future Neurology 2012 March; 7(2): 193-207.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Katz Sand did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.